Table 11. Patients’ characteristics.
| Characteristics | n (%) or mean ± SD/median (min, max) |
|---|---|
| Primary EOC | 35 (61.4) |
| Upfront CRS + HIPEC | 3 (5.3) |
| Interval CRS + HIPEC | 32 (56.1) |
| Recurrent EOC | 22 (38.6) |
| Platinum-sensitive | 7 (12.3) |
| Missing | 15 (26.3) |
| FIGO stage | |
| IIIC | 46 (80.7) |
| IV | 10 (17.5) |
| Missing | 1 (1.8) |
| Grading | |
| G1 | 2 (3.5) |
| G2 | 5 (8.8) |
| G3 | 44 (77.2) |
| Missing | 6 (10.5) |
| BRCA status | |
| BRCA wild type | 11 (19.3) |
| Missing | 46 (80.7) |
| Histology | |
| Epithelial adenocarcinoma NOS | 5 (8.8) |
| Serous adenocarcinoma | 44 (77.1) |
| Clear-cell adenocarcinoma | 1 (1.8) |
| Endometrioid carcinoma | 6 (10.5) |
| Mucinous adenocarcinoma | 1 (1.8) |
| PCI | |
| PCI <15 | 36 (63.2) |
| PCI ≥15 | 20 (35.1) |
| Missing | 1 (1.8) |
| CC | |
| CC-0 | 51 (89.5) |
| CC-1 and CC-2 | 6 (10.5) |
| HIPEC regimen | |
| Cisplatin + Taxol | 48 (84.2) |
| Cisplatin + Mitomycin | 2 (3.5) |
| Cisplatin + Doxorubicin | 5 (8.8) |
| Cisplatin alone | 2 (3.5) |
| Pre-HIPEC chemotherapy regimen | |
| Primary EOC (n=35) | |
| NACT | 30 (85.7) |
| Carboplatin + Taxol | 2 (5.7) |
| Carboplatin + Taxol + Bevacizumab | |
| No NACT | 3 (8.6) |
| In recurrent EOC (n=22) (more than one regimen for each patient) | |
| Carboplatin + Taxol | 16 (72.7) |
| Bevacizumab | 5 (22.7) |
| Niraparib | 1 (4.5) |
| Doxorubicin | 6 (27.3) |
| Trabectedin | 3 (13.6) |
| Gemcitabine | 2 (9.0) |
| Etoposide | 1 (4.5) |
| Age | 58.33±8.64/59 (42–73) |
| PCI | 11.93±9.18/12 (0–37) (IQR 15) |